2021 CMSC Annual Meeting

Tag: (2)Biogen

Poster-Quality of Life and Outcomes

Characterizing Activities of Daily Living in MS Patients with Processing Speed Scores Above and below a Threshold Previously Shown to Predict Employment Status

Background: Cognitive impairment can occur early in the course of multiple sclerosis (MS) and worsen progressively over time, impacting...

Read More

Poster-Disease-modifying Therapy

COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths

Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...

Read More

Poster-Disease-modifying Therapy

Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data

Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...

Read More

Platform-Disease Modifying Therapies

COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy

Background: COVID-19 is a potentially fatal respiratory illness, caused by the novel coronavirus, SARS-CoV-2, which developed into the...

Read More